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Retrospective Analysis of Guideline Recommended Antiretroviral Regimens and Vaccination
Schedules for Adult Patients with Human Immunodeficiency Virus (HIV) in an Infectious Diseases Clinic
Jose Alejandro Roman, PharmD, Jarrod Kile, RPh, BCPS, Amy Slenker, MD, Hope Kincaid, MPH, CPH
Lehigh Valley Health Network, Allentown, PA

PURPOSE

This study will evaluate the management of patients diagnosed with HIV in an
outpatient infectious diseases practice compared to evidence based guidelines.
The 2018 guidelines from the International Antiviral Society (IAS) recognize
three treatment regimens as “Recommended Initial Regimens for Most People
with HIV.” These are listed below. Demographic information of this patient
population will be collected to determine which factors, if any, are significantly
different for patients on less strongly recommended antiretroviral medications.
The percentage of patients who received first line recommended antiretroviral
regimens will be reported to assess the adherence with current guidelines.
Rates of increased viral load above 200 HIV RNA copies/mL and CD4 cell
counts below 200 cells/mm3 will be characterized and analyzed for this patient
population. A qualitative analysis will be completed to identify the rationale
behind the initiation of each patient’s antiretroviral regimen. These described
contraindications will be compared with the IAS guideline recommendations to
act as an objective measure for appropriateness of care. Percentage of patients
who received recommended vaccines will also be evaluated as patients with
HIV are at an increased risk for vaccine preventable diseases due to the nature
of immunosuppression.

PREFERRED ANTIRETROVIRAL REGIMENS
FOR THE TREATMENT OF HIV

Based on the International Antiviral Society 2018 guideline recommendations
Available in a single pill formulation that contains an integrase inhibitor
Listed in alphabetical order by generic name of the integrase inhibitor
component:
• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate)
• Triumeq (dolutegravir/abacavir/lamivudine)
• Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate)

PRIMARY OBJECTIVE

Determine if there is a difference in demographic information associated with
patient populations on certain treatment regimens for HIV.

SECONDARY OBJECTIVES

• Calculate the percentage of patients at this outpatient infectious diseases

clinic whom were receiving first line recommended medications as of their
most recent office visit on or before June 30th, 2018
• Of those patients not on first line recommended regimens, determine
the various contraindications to first-line recommended therapy
(Qualitative analysis)
• Characterize the distribution of most recent CD4 cell counts of all patients
• Calculate the percentage of patients with undetectable viral load
• Compare the viral loads between patients on various regimens
• Compare the CD4 cell counts between patients on various regimens
• Calculate the percentage of patients who have received each of the
recommended vaccinations according to ACIP guidelines

DEMOGRAPHIC DATA TO BE COLLECTED
Age
Gender
Race
Weight
Current
Insurance Status
Sexual
Orientation
Time since
HIV Diagnosis
Substance Use

METHODS

Retrospective chart review utilizing EPIC electronic medical record of patients
who are:
• HIV positive
• Managed at LVPG outpatient infectious diseases clinic
Charts will be reviewed for antiretroviral regimen, vaccination history, and
laboratory values using clinician notes, prescription lists, and medication
administration records between February 1, 2015 and June 30, 2018.

INCLUSION CRITERIA

Inclusion in the study will be limited to a maximum of 100 patients. If more
than 100 patients are eligible for inclusion, the 100 patients with appointment
dates chronologically closest to June 30, 2018 will be included in the analysis.
• Age older than 18 years
• Diagnosis of HIV-1
• Attended appointment at least once between July 1, 2017 and June 30, 2018

Hepatitis B Virus (HBV)
Hepatitis C Virus (HCV)
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Hypertension (HTN)
Hyperlipidemia (HLD)
Atherosclerotic Cardiovascular Disease (ASCVD)
Tuberculosis (TB)
Chronic Lung Disease (CLD)
History of Transplant Surgery
History of Splenectomy

IMMUNIZATION RECOMMENDATIONS

Recommend the administration of vaccines at the same schedules in all
individuals regardless of CD4 count except for certain live virus vaccines
Based on the Advisory Committee on Immunization Practices (ACIP) Adult
Immunization Recommendations.
Live viruses that should be avoided when the CD4 count is ≤ 200 cells/mm3
• Mumps/measles/rubella vaccine
• Herpes zoster vaccine
• Varicella (chicken pox) vaccine

ASSESSED VACCINATIONS
• Influenza

• Hepatitis A

• Pneumococcal conjugate

• Hepatitis B

• Pneumococcal polysaccharide

• Meningococcal

• Tetanus toxoid/diphtheria/pertussis

• Mumps/measles/rubella

• Human Papilloma Virus

• Herpes Zoster Virus

STATISTICAL ANALYSIS

Descriptive statistics for the sample as a whole will be calculated and
presented.
Statistical comparisons between the demographic variables between groups,
based on the various treatment regimens, will then be completed.
• Chi-square Test of Independence will be used for categorical variables
If > 20% of the expected cell counts are found to be < 5, the Fisher’s
Exact Test will alternatively be used
• ANOVA will be used to compare continuous variables between groups
If the distribution of variables in any of the groups is skewed, the KruskalWallis Test will alternatively be used
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• Varicella
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